Ellipsys Vascular Access System Post Market Surveillance (PS) Study

1. Male or non-pregnant female ≥ 18 years of age and ≤ 80 years of age

2. Life expectancy of at least one year, in the investigator's opinion

3. Diagnosed with ESRD or chronic kidney disease on hemodialysis.

4. Patients deemed medically eligible for upper extremity autogenous AV fistula creation, per institutional guidelines and/or clinical judgment

5. Adequate quality vein based on pre-operative assessment

6. Adequate quality radial artery based on pre-operative assessment a. Arterial lumen diameter of ≥2.0 mm at target anastomosis site

7. Adequate collateral arterial perfusion with patent palmar arch as demonstrated by Barbeau Test or Allen's Test.

8. Radial artery-adjacent vein proximity ≤1.5 mm measured lumen edge-to-lumen edge as determined by pre-procedural ultrasound and confirmed pre-procedure

9. Patient is able to provide written informed consent and attend follow-up examinations at the enrolling institution Imaging-based Inclusion Criteria:

10. Confirm radial artery-adjacent vein proximity ≤1.5 mm measured lumen edge-to-lumen edge as determined by pre-procedural ultrasound and confirmed pre-procedurally

11. Confirm radial artery and adjacent vein diameter of ≥2.0 mm at target anastomosis site

1. Pre-existing ipsilateral vascular disease interfering with the study procedure or potentially confounding the study results including:

2. Prior vascular surgery at or proximal (central) to the AVF target site interfering with AVF maturation or other ipsilateral surgery that could potentially confound the study results such as prior axillary dissection or mastectomy

3. History of steal syndrome from a previous surgical ipsilateral hemodialysis vascular access which required intervention or abandonment

4. Systolic pressures < 100 mg Hg at the time of screening

5. Suspected or confirmed skin disease at the skin entry site

6. Edema of the upper extremity on the ipsilateral side

7. Immunocompromised subjects due to underlying disease or immunosuppressant therapy such as sirolimus (Rapamune®) or Prednisone at a dose of > 10 mg per day

8. Known bleeding diathesis, coagulation disorder or medications putting the subject at increased risk, in the Investigator's judgment

9. Patients with acute or active infection

10. Scheduled kidney transplant within 6 months of enrollment

11. Participation in another clinical investigation (excluding retrospective studies or studies not requiring a consent form)

12. History of substance abuse or anticipated to be non-compliant with medical care or study requirements based on investigator judgment

13. Patient has an active COVID-19 infection with ongoing sequela or hospitalization for treatment of COVID-19.